Welcome back to another HCP Live Cure Connections series. In this episode “Diagnosis and Early Treatment in IBD”, the panel explores the early patient journey in inflammatory bowel disease (IBD), including the onset of symptoms, the path to diagnosis, and the transition to specialty gastroenterology care.
In this episode, “Navigating Biologic Therapy Options in IBD,” the panelists explore the evolving treatment journey for patients with inflammatory bowel disease (IBD), including experiences with biologic therapies and the path toward remission.
Crohn’s patient and GI expert share symptom-to-diagnosis clues and biologic options that overcome access worries and support remission.
Learn how clinicians personalize Crohn’s treatment, why early therapy matters, and how IL‑23 options like guselkumab fit.
Crohn’s patient shares how switching to golimumab brings fast relief, safer monitoring, and a return to normal meals after biologic worries.
Learn how fast insurance approvals, ongoing testing, and staying on therapy help manage chronic IBD and improve quality of life.
Learn how IBD patients get fast access to Tremfya, navigate insurance, and stay in remission with ongoing tests and doctor teamwork.
Learn why controlling IBD matters more than feared side effects, and how biologics, monitoring, and whole-person care restore normal life.
Embarrassing gut issues deserve answers: testing can uncover IBS or Crohn’s, and early biologic treatment helps achieve remission.
Unpack embarrassing gut symptoms, learn why “IBS” may mask Crohn’s, and see how honest talks, tests, and biologics lead to remission.
